BRIEF-Promis Neurosciences reports q1 2017 annual results

* Says announced mr. Daniel geffken to position of chief financial officer

* Promis will focus on progressing pmn 310, its lead development product, to ind submission anticipated by end of 2018

* Promis Neurosciences Inc - . Priority for 2017 is to actively pursue development of precision medicine therapeutics for ad and als

* Promis Neurosciences - net loss for three months ended march 31, 2017 of $1.4 million versus net loss of $670,150 for three months ended March 31, 2016 Source text for Eikon: Further company coverage: